About HizentraSCIg TherapyEfficacySafety and TolerabilityAdverse ReactionsDosage and AdministrationSelf Administration VideoDosage CalculatorInitiating HizentraAssistance and SupportSHARE Nurse Training and ExamInfusion Support CenterProfessional ResourcesFrequently Asked QuestionsRequest More InformationImportant Safety Information

Hizentra Dosage Calculator

The Hizentra dosage calculator can save you time when determining the recommended dose of Hizentra for your patients. Simply enter the numbers in the empty fields below and click on the "Calculate" button. To clear the fields or to start over, click on the "Reset" button.

Adjust the dose over time based on clinical response and serum IgG trough levels.

Here is the formula used by the calculator:



  • * To convert to mL, grams are multiplied by 5.
 

Support for you and your patients

Find a variety of professional resources, useful links, and clinical publications about Hizentra.

View resources
Find nurses trained in SCIg therapy

Important Safety Information

Immune Globulin Subcutaneous (Human), Hizentra®, is indicated as replacement therapy for patients with primary humoral immunodeficiency (PI), age 2 and older. This includes but is not limited to the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

Hizentra is contraindicated in patients with a history of anaphylactic or severe systemic reaction to human immune globulin preparations or components of Hizentra, such as polysorbate 80. Because it contains the stabilizer L-proline, Hizentra is contraindicated in patients with hyperprolinemia. Hizentra is also contraindicated in patients with immunoglobulin A deficiency who have antibodies against IgA and a history of hypersensitivity.

Hizentra should be administered subcutaneously only. Do not administer intravenously.

IgA-deficient patients with anti-IgA antibodies may be at greater risk of developing potentially severe hypersensitivity and anaphylactic reactions with administration of Hizentra. If hypersensitivity occurs or anaphylactic reactions are suspected, discontinue administration immediately and treat as medically appropriate.

Hizentra is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

The most common drug-related adverse reactions (observed in 5% or more of study subjects receiving Hizentra) were local reactions (ie, swelling, redness, heat, pain, and itching at the injection site), headache, diarrhea, fatigue, back pain, nausea, extremity pain, cough, rash, pruritis, vomiting, upper abdominal pain, pain, and migraine.

Monitor patients for thrombotic events and aseptic meningitis (AMS), which have been reported with SCIg. Also look forreactions reported to occur with IVIg treatment that might also occur with Hizentra, including renal dysfunction/failure, hemolysis, and transfusion-related acute lung injury (TRALI).

Ig administration can transiently impair the efficacy of live attenuated virus vaccines, such as measles, mumps and rubella. It can also lead to misinterpretation of serologic testing.

Please see full prescribing information for Hizentra.